psoriasis

Sulzberger lecturer provides in-depth look at psoriasis comorbiditiesIn his talk at AAD 2017, Joel M. Gelfand, MD, MSCE, discussed the findings from research investigating associations between psoriasis and comorbidities and their relevance for providing comprehensive medical care for patients with psoriasis.
How psoriasis arisesThe research road to streamlining the model of psoriasis pathogenesis.
Psoriasis treatment in skin of color
Psoriasis treatment in skin of colorWhen it comes to treating psoriasis in non-white patients, there is a paucity of data on differences in epidemiology, clinical presentation and approaches to treatment.
Earlier diagnosis of psoriatic arthritis will prevent disease progression
Earlier diagnosis of psoriatic arthritis will prevent disease progressionPsoriatic arthritis can often go undiagnosed in patients with psoriasis, and an earlier diagnosis is critical to prevent the adverse effects of psoriatic arthritis, according to an expert.
July Clinical ConsiderationsIn this month's Clinical Considerations, we take a look at biologics and treatments for seborrheic keratoses.
Prescribing barriersDermatologists who plan to prescribe brodalumab may face a rough road.
Biologic class differentiatorsDermatology experts offer insight into differentiating factors among TNF-alpha inhibitors, the IL 12/23 antagonist, IL 17 inhibitors and an oral option that carry considerations for managing certain patients.
A peek at the pipelineThere is tremendous excitement surrounding IL-23 inhibitors for the treatment of psoriasis. Three are currently in the pipeline.
Paradoxical reactions to biologics provide insightParadoxical reactions to biologic treatments can provide clues into related conditions such as granulomatous diseases, genetic polymorphisms and latent infections, says an expert.
Pharmaceutical pipeline: Top 4 conditions to watch
Pharmaceutical pipeline: Top 4 conditions to watchAlthough drug spend is increasing for inflammatory conditions, diabetes, and oncology, there are some promising developments in the pipeline.